Fei Mu

Fei Mu


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 July 2020 in Journal of Diabetes Research
Verified
Journal Article
Open access
PDF file
SHShaojie Huang
Shaojie Huang
FMFei Mu
Fei Mu
FLFei Li
Fei Li
WWWenjun Wang
Wenjun Wang
HCHaixia Chen
Haixia Chen
JWJingwen Wang
Jingwen Wang
Erzhi pill (EZP), a classical traditional Chinese medicine prescription, exerts a potent hepatoprotective effect against metabolic dysfunction-associated fatty liver disease (MAFLD), previously known as nonalcoholic fatty liver disease (NAFLD). However, the mechanism and bioactive compounds underlying the hepatoprotective effect of EZP have not been fully elucidated. In this study, a systematic analytical platform was built to explore the mechanism and bioactive compounds of EZP against MAFLD. This was carried out through target prediction, protein-protein interaction (PPI) network construction, gene ontology, KEGG pathway enrichment, and molecular docking. According to the topological parameters of the PPI network, compound-target-pathway network, 9 targets, and 11 bioactive compounds were identified as core targets and bioactive compounds for molecular docking. The results showed that EZP exerts anti-MAFLD effects through a multicomponent, multitarget, multipathway manner, and luteolin and linarin may be the bioactive compounds of EZP. This study provides further research insights and helps explore the hepatoprotective mechanism of EZP.

1 August 2025 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
XTXingru Tao
Xingru Tao
MZMeina Zhao
Meina Zhao
KGKai Gao
Kai Gao
WZWei Zhang
Wei Zhang
DXDong Xu
Dong Xu
JWJingwen Wang
Jingwen Wang
Purpose: Wedelolactone (Wel), a furocoumarin compound extracted from the medicinal plant Eclipta prostrata L. has been shown to exhibit significant neuroprotective effects. However, the potential of Wel to improve ischemic stroke (IS) and the underlying mechanisms remain unclear. Methods: The middle cerebral artery occlusion and reperfusion (MCAO/R) and oxygen-glucose deprivation/reoxygenation (OGD/R) were established to evaluate the potential neuroprotective of Wel. Neurological function, brain infarct volume, brain swelling, and histopathological staining were analyzed to demonstrate the therapeutic efficacy of Wel. The occurrence of ferroptosis was confirmed by quantifying the levels of ROS and Fe2+, and by examining the ultrastructural features of cells. The binding affinity between Wel and HIF-1α was evaluated using Molecular docking. Immunofluorescence and Western blot analyses were conducted to explore the regulation of Wel on the HIF-1α/SLC7A11/GPX4 pathway. Finally, the expression of HIF-1α was down-regulated to verify whether Wel exerts neuroprotection by modulating HIF-1α to inhibit ferroptosis of cells. Results: The results demonstrated that Wel effectively inhibit neuron ferroptosis after MCAO/R in a dose-time-dependent manner, thereby alleviating brain injury. Moreover, at the cellular level, Wel significantly reduced the accumulation of Fe2+ and ROS after OGD/R. Further investigation revealed that Wel might inhibit neuronal ferroptosis and improve IS by promoting the nuclear translocation and accumulation of HIF-1α, subsequently regulating the expression of downstream proteins SLC7A11 and GPX4. Notably, the inhibitory effect of Wel on ferroptosis was markedly attenuated by HIF- 1α siRNA in OGD/R PC12 cells. Conclusion: Our discovery revealed that the Wel could alleviate IS by inhibiting oxidative damage and ferroptosis via HIF-1α/ SLC7A11/GPX4 signaling pathway. Wel may represent a promising active compound for anti-IS, while also providing novel insights into the elucidation of its molecular mechanisms and potential clinical implications.

1 January 2024 in The American Journal of Chinese Medicine
Verified
Journal Article
Closed access
MZMeina Zhao
Meina Zhao
FMFei Mu
Fei Mu
MXMiaomiao Xi
Miaomiao Xi
KGKai Gao
Kai Gao
WZWei Zhang
Wei Zhang
JWJingwen Wang
Jingwen Wang

19 November 2025 in Redox Biology
Verified
Journal Article
Open access
FMFei Mu
Fei Mu
HZHaiyue Zhang
Haiyue Zhang
RGRui Gong
Rui Gong
RLRui Lin
Rui Lin
MZMeina Zhao
Meina Zhao
JWJingwen Wang
Jingwen Wang
Cardiovascular diseases (CVDs) are life-threatening disorders arising from interactions between genetic and environmental factors, imposing a heavy global health burden with high morbidity and mortality. Emerging evidence suggests that dysregulated epigenetic modifications, particularly lysine succinylation, play a critical role in the pathogenesis of CVD. Characterized by the covalent addition of a succinyl group to lysine residues, succinylation dynamically alters the functions of proteins, including those involved in transcriptional regulation, and directly affects energy metabolism, oxidative stress, inflammation, apoptosis, and fibrosis. This modification has been linked to the development of various CVDs, such as atrial fibrillation, myocardial ischemia-reperfusion injury, myocardial infarction, heart failure, aortic aneurysm and dissection, diabetic cardiomyopathy, hypertrophic cardiomyopathy, and atherosclerosis. Its effects on key biological processes contribute to these conditions through multiple mechanisms. This review systematically summarizes current research on the role of succinylation in cardiovascular pathophysiology, with a particular focus on its function as a "metabolic switch" in CVDs. It further highlights the critical role of succinylation in regulating redox homeostasis and maintaining the balance of SIRT5-mediated desuccinylation. By integrating mechanistic insights from preclinical and clinical studies, we aim to provide a comprehensive framework for understanding the multifaceted roles of succinylation in CVDs and to identify potential therapeutic targets for future translational research.

5 April 2024 in Rejuvenation Research
Verified
Journal Article
Closed access
QDQi Dai
Qi Dai
SZShi Zhao
Shi Zhao
WLWeihong Li
Weihong Li
KLKedi Liu
Kedi Liu
XTXingru Tao
Xingru Tao
MXMiaomiao Xi
Miaomiao Xi
Astragali radix (AR) and anemarrhenae rhizoma (AAR) are used clinically in Chinese medicine for the treatment of chronic heart failure (CHF), but the exact therapeutic mechanism is unclear. In this study, a total of 60 male C57BL/6 mice were divided into 5 groups, namely sham, model, AR, AAR, and AR-AAR. In the sham group, the chest was opened without ligation. In the other groups, the chest was opened and the transverse aorta was ligated to construct the transverse aortic constriction model. After 8 weeks of feeding, mice were given medicines by gavage for 4 weeks. Left ventricular ejection fraction (LVEF) and left ventricular fractional shortening (LVFS) were detected by echocardiography. Heart weight index (HWI) and wheat germ agglutinin staining were used to evaluate cardiac hypertrophy. Hematoxylin–eosin staining was used to observe the pathological morphology of myocardial tissue. Masson staining was used to evaluate myocardial fibrosis. The content of serum brain natriuretic peptide (BNP) was detected by enzyme-linked immunosorbent assay kit. The content of serum immunoglobulin G (IgG) was detected by immunoturbidimetry. The mechanism of AR-AAR in the treatment of CHF was explored by proteomics. Western blot was used to detect the protein expressions of complement component 1s (C1s), complement component 9 (C9), and terminal complement complex 5b-9 (C5b-9). The results show that AR-AAR inhibits the expression of complement proteins C1s, C9, and C5b-9 by inhibiting the production of IgG antibodies from B cell activation, which further inhibits the complement activation, attenuates myocardial fibrosis, reduces HWI and cardiomyocyte cross-sectional area, improves cardiomyocyte injury, reduces serum BNP release, elevates LVEF and LVFS, improves cardiac function, and exerts myocardial protection.

1 October 2025 in Journal of Inflammation Research
Verified
Journal Article
Open access
PDF file
LZLulu Zhang
Lulu Zhang
YYYanping Yin
Yanping Yin
LZLingling Zheng
Lingling Zheng
YWYiwen Wang
Yiwen Wang
JZJinyi Zhao
Jinyi Zhao
JWJingwen Wang
Jingwen Wang
Background: Sepsis-induced cardiomyopathy (SICM) is a common and serious complication in patients with sepsis and septic shock. Its pathological and physiological mechanisms are highly complex and often lead to dysfunction of multiple organ systems, and the current clinical intervention strategies have limited efficacy. Statins have been shown to reduce mortality of sepsis patients and alleviate multi-organ damage caused by sepsis, including SICM. However, the molecular mechanisms by which atorvastatin (ATO) exerts cardioprotective effects have not been fully elucidated. This study aims to systematically explore the cardioprotective effect of ATO on SICM through in vivo and in vitro experiments, and to elucidate the molecular mechanism underlying ATO’s cardioprotective effects. Methods: Mice were exposed to multi-bacterial sepsis through cecal ligation and puncture (CLP) surgery, and were continuously pretreated with ATO for 6 days before surgery. Cardiac function was evaluated by echocardiography. Immunohistochemistry and Western blotting were used to investigate the protective effect of ATO on heart injury in septic mice. AutoDock software, CETSA and DARTS experiments were used to verify the specific binding of ATO to METTL3. Furthermore, the regulatory role of METTL3-mediated m6A modification in septic myocardial inflammatory injury and its molecular mechanisms were elucidated by m6A-MeRIP-seq, RNA immunoprecipitation and Western blotting. Results: ATO could obviously improve the cardiac function of septic mice, alleviate the heart tissue damage, and inhibit the release of inflammatory factors and myocardial injury factors. Mechanically, ATO binds to METTL3 with high affinity and inhibits its expression, thereby suppressing the overall m6A modification level in heart tissue of septic mice and in lipopolysaccharide (LPS)-stimulated cardiomyocytes. Importantly, METTL3 promoted CXCL2 expression by mediating m6A modification of CXCL2 mRNA and enhancing the stability of CXCL2 mRNA in an IGF2BP1 dependent manner. The high expression of CXCL2 eventually triggers the inflammatory response and ferroptosis of cardiomyocytes, resulting in septic myocardial injury. Conclusion: This study elucidates that the METTL3 (m6A)/IGF2BP1/CXCL2 axis promotes the pathological progression of SICM, and ATO exerts cardioprotective effects by targeting this pathway, providing new insights into the significance of RNA m6A modification in SICM.